\odot \odot \odot \odot

Effect of Two Different Temperature Settings on Patient Comfort Level during Respiratory Therapy by High-Flow Nasal Cannula

Mamta Kumari¹ Rashmi Taneja¹ Niharika Grover¹

¹ Megha Soni¹

¹ Department of Anaesthesia, Operation theater complex 3rd floor, ESIC Medical College, NH-3, Faridabad, India Address for correspondence Megha Soni, MBBS, DA, DNB Anaesthesia, Assistant Professor, Department of Anaesthesia, Operation Theater Complex 3rd floor, ESIC Medical College, NH-3, Faridabad, India (e-mail: meghasoniarora@gmail.com).

Int J Recent Surg Med Sci 2023;9:6-11.

Abstract	 Background Hypoxemic respiratory failure may require high flow O₂ therapy (>15 L/m), which can be delivered using a high-flow nasal cannula (HFNC) device. There are three variables: FiO₂, flow, and temperature that can be controlled while using HFNC. This study was planned to assess the degree of comfort level of patients at two different temperature settings. Methods A prospective interventional cross-over study was performed on 40 hypoxemic respiratory failure patients, who were on HFNC. Primary outcome was to assess
	patient comfort during HFNC therapy at two different temperatures (31 and 37°C), at the flow of 60 L/m for 30 minutes at each temperature setting, leaving FiO_2 unchanged. After 30 minutes of each temperature setting, the comfort level was assessed using 11 score visual numerical scale (ranging from 0 to 10) together with other vital parameters.
	than at 37°C (<i>p</i> -value < 0.05%). Also, an increase in blood pressure was observed at 37°
Keywords ► high-flow nasal canula	C after completion of 30 minutes, which was statistically significant but not clinically significant.
temperaturecomfort level	Conclusion Starting HFNC therapy at lower temperature gives better patient acceptance and reduces chances of failure due to discomfort.

Introduction

Oxygen (O₂) therapy is the first step to prevent and manage hypoxemic respiratory failure. High flows (>15 L/m),¹ such as 30 L/m and 60 L/m can be easily delivered using HFNC. It has shown to have better tolerance and comfort level than conventional devices.^{2–4}

Different parameters of HFNC device (FiO₂, flow, and temperature) can be controlled independently. There are studies comparing patient comfort level between NIV and

article published online April 14, 2022 DOI https://doi.org/ 10.1055/s-0042-1745746. ISSN 2455-7420. HFNC but there is a need to know the optimal settings of HFNC to achieve adequate patient comfort level. So, we planned this study to compare the degree of patient comfort level at different temperature settings of HFNC.

Materials and Methods

This prospective interventional cross-over study was carried out after patient's informed written consent, Institutional

© 2022. Medical and Surgical Update Society. All rights reserved. This is an open access article published by Thieme under the terms of the Creative Commons Attribution-NonDerivative-NonCommercial-License, permitting copying and reproduction so long as the original work is given appropriate credit. Contents may not be used for commercial purposes, or adapted, remixed, transformed or built upon. (https://creativecommons.org/ licenses/by-nc-nd/4.0/)

Thieme Medical and Scientific Publishers Pvt. Ltd., A-12, 2nd Floor, Sector 2, Noida-201301 UP, India

Ethics Committee approval, and CTRI registration (CTRI number- CTRI/2021/07/035224). Confidentiality of subjects was maintained. The procedures followed were in accordance with the ethical standards of the institutional committee on human experimentation and with the Helsinki declaration of 1975, as revised in 2000.

A total of 40 non-sedated patients on HFNC with appropriate sized nasal cannula at a flow rate of 60 L/min (as per the inclusion and exclusion criteria) participated in the study.

Inclusion criteria–Patients admitted in the ICU with age between 18 and 65 years on HFNC (Optiflow, Fisher & Paykel Healthcare, Auckland, New Zealand) Exclusion criteria– Patients admitted in the ICU with age < 18 years and > 65 years, hemodynamic instability, altered mental status, patients on non-invasive ventilation, intubated or tracheostomized, pregnant patients, and febrile or hypothermic patients

The primary objective of the study was to assess all 40 patients for the degree of comfort using 11 score visual numerical scale (VNS) ranging from 0 to 10 at the end of 30 minutes, each for two different temperature settings.

Secondary objective was to compare the changes noted in the vital parameters such as heart rate (HR), systolic blood pressure (SBP), diastolic blood pressure (DBP), respiratory rate (RR), and SpO₂, at the end of each step.

Group A-temperature setting of 31° C and flow at 60 L/min.

Group B-temperature setting of 37° C and flow at 60 L/min.

Patients were placed in a semi-recumbent position in a calm environment. Baseline parameters of all non-sedated patients already on HFNC (Fisher & Paykel Healthcare) who were on a flow of 60 L/m (as advised by the ICU physician) were recorded such as HR, SBP, DBP, RR and SpO₂. Every patient included in the study, on HFNC, temperature was set to 31°C. Patients were allowed to stay calm, by their own self for duration of 30 minutes. After 30 minutes, vital parameters were recorded and VNS score was asked. Temperature settings were changed to 37°C. Again, patients were left undisturbed for a period of 30 minutes, following which, comfort level and vital parameters were assessed. All data were recorded by the personnel other than the person who set the temperature for the HFNC device.

Results

There were no drop outs in the study; comfort level of all recruited 40 patients could be assessed as proposed in the study. The data collected are expressed as mean \pm standard deviation (SD) with 95% confidence level. Mean differences were calculated from readings at 31°C minus 37°C. Paired *t*-test was applied to compare the variables. A *p*-value < 0.05 was considered statistically significant.

As this was a cross-over study, patients allotted in each of the two groups were same; hence, mean age and sex were same for the two groups. The mean age was 44.6 ± 2.33 years, and out of the 40 subjects, 24 were males and 16 females.

Table	1	Results	of	change	in	variables	at	two	different
tempe	rat	ures							

Variable	$Mean\pm SD$	Mean difference	p-Value
VNS (31°C) VNS (37°C)	$\begin{array}{c} 8.3 \pm 0.60 \\ 5.4 \pm 0.54 \end{array}$	2.9	0.000
HR (31°C) HR (37°C)	$\begin{array}{c} 84.2 \pm 9.88 \\ 84.5 \pm \ 9.03 \end{array}$	-0.3	0.634
SBP (31°C) SBP (37°C)	$\begin{array}{c} 118.5 \pm 9.57 \\ 120.5 \pm 9.44 \end{array}$	-2	0.000
DBP (31°C) DBP (37°C)	$76.7 \pm 8.72 \\ 78.3 \pm 7.63$	-1.5	0.005
MAP (31°C) MAP (37°C)	$\begin{array}{c} 89.9 \pm 8.24 \\ 91.8 \pm 7.92 \end{array}$	-1.8	0.000
SpO ₂ (31°C) SpO ₂ (37°C)	$\begin{array}{c} 97.8 \pm 0.81 \\ 97.8 \pm 0.66 \end{array}$	-0.025	0.830
RR (31°C) RR (37°C)	$20.0 \pm 1.42 \\ 19.9 \pm 1.19$	0.175	0.484

*Abbreviations: DBP, diastolic blood pressure; HR, heart rate; MAP, mean arterial blood pressure; RR, respiratory rate; SpO₂, oxygen saturation; SBP, systolic blood pressure; SD, standard deviation; VNS, visual numeric scale.

[†]Temperature at which reading is noted in brackets.

[‡]Mean differences were calculated from readings at temperature of 31° C minus 37°C.

Comfort level–Patients were found to be more comfortable in group A in comparison to those in group B with a mean difference of 2.9 VNS at two temperatures (p < 0.05%), which was clinically as well as statistically significant (**-Table 1**, **-Fig. 1**).

Vital signs–Group B showed an increase in SBP, DBP, and MAP after completion of 30 minutes as compared to group A (p < 0.05), which was statistically significant although mean differences were not that profound, showing no clinical significance (**~Table 1**, **~Figs. 2–4**).

Other variables such as HR, SpO_2 , and RR were not clinically as well as statistically significant (p > 0.05) (**-Table 1**, **-Figs. 5–7**).

Discussion

Earlier O₂ therapy in spontaneously breathing patients were possible by nasal prongs and facemasks, which work well at flows of up to 10 L/m. High-flow O₂ therapy (>15 L/m) may lead to drying of nasal mucosa even with bubble humidification due to air entrainment. Higher flows of totally conditioned gas (37°C containing 44 mg H2O/l (100% relative humidity)¹ such as 30 L/m and 60 L/m can be delivered using HFNC.¹ It prevents drying of mucosa, having a protective effect on muco-ciliary function such as secretion clearance and airway defense.

Also, gas conditioning may decrease inflammation of the tracheal mucosa after intubation; hence, the use of HFNC prior to extubation, prevents the administration of dry and cold air in the native airway of the patients, causing fewer reintubations secondary to upper airway obstruction and also, accelerated weaning in tracheostomized persons.^{2,5}





Visual Numeric Scale 37





Fig. 2 Systolic blood pressure at 31°C and 37°C.







Fig. 4 Mean arterial pressure at 31°C and 37°C.



Fig. 5 Heart rate at 31°C and 37°C.



Fig. 6 Oxygen saturation at 31°C and 37°C.



Fig. 7 Respiratory rate at 31°C and 37°C.

Many studies have shown oxygenation enhancement and reduction in the respiratory rate by early application of HFNC compared to standard oxygen therapy.^{2–4} It has shown positive clinical impact on patients with acute hypoxemic respiratory failure.^{6–8} HFNC has better tolerance and comfort than non-invasive ventilation (NIV).^{9,10} HFNC reduces intubation rate, increasing ventilator-free days, and reduced 90-day mortality. However, the rate of intubation in patients on HFNC and NIV were found to be similar in many studies^{11–13} with studies showing better oxygenation with NIV.^{9,10}

Better comfort levels help in improving the tolerance for any undergoing procedure. Recently, FLORALI study (post hoc analysis) showed intubation within 1 hour of starting HFNC due to discomfort, suggesting a strong link between discomfort and poor outcomes.¹⁴ Comfort level is a patientlevel outcome generated on the basis of various physiologic mechanisms.^{15,16} Various physiological studies have been conducted before to measure comfort level in patients on non-invasive respiratory support, scale used was the same as in this study, i.e., VNS.¹⁷⁻¹⁹

In this study, patients were found to be more comfortable at lower temperature of 31°C than 37°C at 60 L/min of flow of HFNC. Marginal rise in SBP, DBP, and MAP was observed at higher temperatures, which was statistically significant but not clinically significant.

Comfort level is higher at lower temperatures and may suggest negative psychosomatic and physiologic signals such as excessive heating of nostrils in spite of the advantage of maximum humidity.¹⁷ However, because the heating and moisturizing function of the upper airway is preserved during use of the HFNC, starting HFNC at lower temperatures and gradually increasing it with time may be a considered, it may lead to better clinical outcomes such as better tolerance, longer duration of HFNC application, and improved comfort. Patients showed different comfort levels at different temperatures, may point toward personalizing the settings on individual basis rather than using fixed standard settings.²⁰ Certain limitations pertinent to study are: firstly, our primary aim was subjective psychological outcome. Comfort level according to the temperature may be variable, and differ on person to person basis. Secondly, observation time in our study is limited to 30 minutes. Patient may show discomfort in a longer time of surveillance. Thirdly, ventilator settings including FiO₂ were not considered in baseline comparisons, which may affect comfort levels. Fourthly, midway settings such as 34°C were not assessed, only extreme values were considered. Fifthly, larger studies with bigger sample size may validate our findings.

Conclusion

Starting HFNC therapy at lower temperature gives better patient acceptance and reduces chances of failure due to discomfort. Gradually temperature may be increased or adjusted on personalized basis according to the patients comfort. To use comfort level as a guide to HFNC settings as a non-invasive respiratory support, larger studies are needed for its validation.

Authors' Contributions

Dr. Mamta Kumari– concept, design, literature search. Dr. Megha Soni- data acquisition, literature search. Dr. Niharika Grover-literature search, definition of intellectual content, manuscript preparation. Dr. Rashmi Taneja – manuscript editing and review.

Dr. Mamta Kumari is the guarantor and takes the responsibility for the integrity of work as a whole from inception to published article.

Declaration

This manuscript has been read and approved by all the authors, requirements for authorship have been met, and each author believes that the manuscript presents the honest work. Article is not published nor under consideration, in part or whole simultaneously in any other journal or any other proceedings.

Funding

This study was funded by the ESIC Medical College, NH-3, Faridabad.

Conflicts of Interest

None declared.

References

- 1 Hernández G, Roca O, Colinas L. High-flow nasal cannula support therapy: new insights and improving performance. Crit Care 2017;21(01):62
- 2 Roca O, Riera J, Torres F, Masclans JR. High-flow oxygen therapy in acute respiratory failure. Respir Care 2010;55(04):408–413
- ³ Sztrymf B, Messika J, Mayot T, Lenglet H, Dreyfuss D, Ricard JD. Impact of high-flow nasal cannula oxygen therapy on intensive care unit patients with acute respiratory failure: a prospective observational study. J Crit Care 2012;27(03):324.e9–324.e13
- 4 Sztrymf B, Messika J, Bertrand F, et al. Beneficial effects of humidified high flow nasal oxygen in critical care patients: a prospective pilot study. Intensive Care Med 2011;37(11): 1780–1786
- 5 Hernández G, Vaquero C, González P, et al. Effect of postextubation highflownasal cannula vs conventional oxygen therapy on reintubation in lowrisk patients. A randomized clinical trial. JAMA 2016;315(13):1354–1361
- 6 Frat JP, Thille AW, Mercat A, et al; FLORALI Study Group REVA Network. High-flow oxygen through nasal cannula in acute hypoxemic respiratory failure. N Engl J Med 2015;372(23):2185–2196
- 7 Delorme M, Bouchard PA, Simon M, Simard S, Lellouche F. Effects of high-flow nasal cannula on the work of breathing in patients recovering from acute respiratory failure. Crit Care Med 2017;45 (12):1981–1988
- 8 Azoulay E, Pickkers P, Soares M, et al; Efraim investigators and the Nine-I study group. Acute hypoxemic respiratory failure in immunocompromised patients: the Efraim multinational prospective cohort study. Intensive Care Med 2017;43(12):1808–1819
- 9 Frat JP, Brugiere B, Ragot S, et al. Sequential application of oxygen therapy via high-flow nasal cannula and noninvasive ventilation

in acute respiratory failure: an observational pilot study. Respir Care 2015;60(02):170–178

- 10 Schwabbauer N, Berg B, Blumenstock G, Haap M, Hetzel J, Riessen R. Nasal high-flow oxygen therapy in patients with hypoxic respiratory failure: effect on functional and subjective respiratory parameters compared to conventional oxygen therapy and non-invasive ventilation (NIV). BMC Anesthesiol 2014;14:66–73
- 11 Patel BK, Wolfe KS, Pohlman AS, Hall JB, Kress JP. Effect of noninvasive ventilation delivered by helmet vs face mask on the rate of endotracheal intubation in patients with acute respiratory distress syndrome: a randomized clinical trial. JAMA 2016; 315(22):2435–2441
- 12 Liu Q, Gao Y, Chen R, Cheng Z. Noninvasive ventilation with helmet versus control strategy in patients with acute respiratory failure: a systematic review and meta-analysis of controlled studies. Crit Care 2016;20:265–279
- 13 Hernández G, Vaquero C, Colinas L, et al. Effect of postextubation high-flow nasal cannula vs noninvasive ventilation on reintubation and postextubation respiratory failure in high-risk patients: a randomized clinical trial. JAMA 2016;316(15):1565–1574
- 14 Frat JP, Ragot S, Coudroy R, et al; REVA network. Predictors of intubation in patients with acute hypoxemic respiratory failure treated with a noninvasive oxygenation strategy. Crit Care Med 2018;46(02):208–215
- 15 Kolcaba K, Tilton C, Drouin C. Comfort Theory: a unifying framework to enhance the practice environment. J Nurs Adm 2006;36 (11):538–544
- 16 Krinsky R, Murillo I, Johnson J. A practical application of Katharine Kolcaba's comfort theory to cardiac patients. Appl Nurs Res 2014; 27(02):147–150
- 17 Mauri T, Galazzi A, Binda F, et al. Impact of flow and temperature on patient comfort during respiratory support by high-flow nasal cannula. Crit Care 2018;22(01):120
- 18 Stéphan F, Bérard L, Rézaiguia-Delclaux S, Amaru PBiPOP Study Group. BiPOP Study Group. High-flow nasal cannula therapy versus intermittent noninvasive ventilation in obese subjects after cardiothoracic surgery. Respir Care 2017;62(09):1193–1202
- 19 Longhini F, Pan C, Xie J, et al. New setting of neurally adjusted ventilatory assist for noninvasive ventilation by facial mask: a physiologic study. Crit Care 2017;21(01):170
- 20 Mauri T, Grasselli G, Pesenti A. Systematic assessment of advanced respiratory physiology: precision medicine entering real-life ICU? Crit Care 2017;21(01):143